Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment

AIDS

Volumn 13, Issue 14, 1999, Pages 1889-1897

  Tozzi, Valerio ^a,d   Balestra, Pietro ^b   Galgani, Simonetta ^e   Narciso, Pasquale ^a   Ferri, Fabrizio ^a   Sebastiani, Gabriella ^a   D'Amato, Carmelo ^a   Affricano, Cesare ^f   Pigorini, Francesco ^e   Pau, Franca Maria ^e   De Felici, Annapaola ^d   Benedetto, Arrigo ^c  

^a Department of Infectious Diseases ^*  (Italy)

^b Inst of Psychology   (Italy)

^c Laboratory of Virology   (Italy)

^d NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^e SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

AIDS dementia complex; Highly active antiretroviral therapy; HIV 1; Neurocognitive impairment; Protease inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; AMNESIA; ARTICLE; ATTENTION; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; DEPTH PERCEPTION; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MALE; MEMORY; MENTAL FUNCTION; MOTOR PERFORMANCE; NEUROPSYCHOLOGICAL TEST; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; VIREMIA; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COGNITION DISORDERS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VIRAL LOAD;

EID: 0032736152     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199910010-00011     Document Type: Article

References (26)

1. Bacellar H, Munoz A, Miller EN, et al. Temporal trends in the incidence of HIV-1 related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992. Neurology 1994, 44:1892-1900.
2. McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors. Neurology 1993, 43:2245-2252.
3. Janssen RS, Nwanyanwu OC, Selik RM, Stehr-Green JK. Epidemiology of human immunodeficincy virus encephalopaty in the United States. Neurology 1992, 42:1472-1476.
4. Schmitt FA, Bigley JW, McKinnis R, Logue PE, Evans RW, Drucker JL. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1988, 319:1573-1578.
5. Sidtis JJ, Gatsonis C, Price RW, et al. Zidovudine for the treatment of the AIDS dementia complex: results of a placebo-controlled trial. Ann Neurol 1993, 33:343-349.
6. Tozzi V, Narciso P, Galgani S, et al. Effects of zidovudine in 30 patients with mild to end-stage AIDS dementia complex. AIDS 1993, 7:638-692.
7. Hammer S, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:723-733.
8. Palella FJ, Delaney KM, Moorman MO, et al. Declining mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
9. Saacktor NC, Lyles RH, McFarlane G, et al. The changing incidence of HIV-1-related neurological disease: 1990-1997. In: Program and Abstract of the 6th Conference on Retrovirusis and Opportunistic Infections, Chicago, 31 January-4 February, 1999 [Abstract 410].
10. Moyle GJ, Sadler M, Hawkins D, Buss N. Pharmacokinetics of saquinavir at steady state in CSF and plasma: correlation between plasma and CSF viral load in patients on saquinavir containing regimens. In: Program and Abstract of the Infectious Diseases Society of America 35th Annual Meeting, San Francisco, 13-16 September, 1997 [Abstract 115].
11. Enting RH, Hoetelmans MW, Lange JMA, Burger DM, Beijnen JH, Portegies P. Antiretroviral drugs and the central nervous system. AIDS 1998, 12:1941-1955.
12. Flexner C. HIV-protease inhibitors. N Engl J Med 1998, 338:1281-1292.
13. Letendre S, Ellis R, Heaton RK, Atkinson JH, Nelson J, Grant I, McCutchan JA. Change in CSF RNA level correlates with the effects of antiretroviral therapy on HIV-1 associated neurocognitive disorder [Abstract]. J Neurovirol 1998, 4:357.
14. Ferrando S, van Gorp W, McElhiney M, Coggin K, Sewell M, Rabkin J. Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function. AIDS 1998, 12:F65-F70.
15. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1993, 41 (RR-17):1-19.
16. American Academy of Neurology. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection: report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology 1991, 41:778-785.
17. Pau FM, Rosci MA, Bernabei A, et al. 99mTc-HMPAO SPECT in asymptomatic HIV-1 infected patients. Preliminary results. J Nucl Med Allied Sci 1990, 14:213-214.
18. Robertson K, Fiscus S, Wilkins J, van der Horst C, Hall C. Viral load and neuropsychological functioning in HIV seropositive individuals: a preliminary descriptive study. J NeuroAIDS 1997, 1:7-15.
19. McArthur JC, McClernon D, Cronin M, Nance-Sproson T, Saah A, St Clair M, Lanier R. Relationship between HIV-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 1997, 42:689-698.
20. Robertson K, Fiscus S, Kapoor C, et al. CSF, plasma viral load and HIV associated dementia. J Neurovirol 1998, 4:90-94.
21. Eggers C, Van Lunzen J, Stellbrink HJ. Rapid decay of HIV-RNA in the cerebrospinal fluid during combination antiretroviral therapy [Abstract]. J Neurovirol 1998, 4:348.
22. Cunningham P, Smith D, Satchell C, Cooper DA, Brew BJ. Evidence for independent development of RT inhibitor (RTI) resistance patterns in cerebrospinal fluid (CSF) compartment. In: Program and Abstract of the 12th World AIDS Conference, Geneva, Switzerland, 28 June-3 July, 1998 [Abstract 563/32284].
23. Sacktor N, Prohovnik R, Van Heerturn R, et al. Cerebral SPECT abnormalities in HIV-1 infected gay man without cognitive impairment. J Nucl Med 1994, 35:115P-119P.
24. Maini CL, Pigorini F, Pau FM, et al. Cortical cerebral blood flow in HIV-1-related dementia complex. Nucl Med Commun 1990, 11:639-684.
25. Brew BJ, Portegies P. Antiretroviral drugs within the CSF. In: The pathogenesis and treatment of HIV CNS infection. London: International Medical Press; 1997:14-15.
26. Letendre SL, Caparelli E, Ellis RJ, Dur D, McCuttan A. Levels of serum and cerebrospinal fluid (CSF) Indinavir (IDV) and HIV-RNA in HIV-infected individuals. In: Program and Abstract of the 6th Conference on Retrovirusis and Opportunistic Infections, Chicago, 31 January-4 February, 1999 [Abstract 407].